RESOURCES FOR AFLURIA TO HELP PROTECT YOUR STAFF AND PATIENTS AGAINST THE FLU

RESOURCES FOR HEALTHCARE PROFESSIONALS AND PHARMACISTS

Prebook Afluria — Click for more important information about Afluria.
  • FLU TIPS AND FACTS
  • INJECTION INSTRUCTIONS

FLU TIPS

Click on the images below to download and print a tips sheet and a poster containing
important flu tips for your office staff and patients.

Flu Tips Sheet Flu Tips Sheet

Flu Tips Poster Flu Tips Poster

Unbranded Flu Facts and Tips Brochure from Seqirus Patient Educational Brochure on Flu Click the image to download a pamphlet for your patients that provides key facts about the flu and flu vaccine.

Unbranded Flu Poster from Seqirus Flu Vaccination Poster for Physicians Click the image to download a poster on the importance of getting a flu vaccine.

Flu Clinic Poster for Pharmacies Flu Vaccination Poster for Pharmacists Click the image to download a poster on the importance of getting a flu vaccine.

INTRAMUSCULAR INJECTION INSTRUCTIONS

How to administer Afluria to adults

AFLURIA HELPS YOUR PATIENTS STAND STRONG AGAINST THE FLU

seqirus

The product information presented on this site is for U.S. residents only. Afluria® Quadrivalent, Afluria®, and Seqirus are trademarks of Seqirus UK Limited or its affiliates. PharmaJet® and Stratis® are registered trademarks of PharmaJet Inc. Manufactured by: Seqirus Pty Ltd Parkville, Victoria, 3052, Australia Distributed by: Seqirus USA Inc. 25 Deforest Avenue, Summit, NJ 07901, USA © 2017 Seqirus USA Inc. www.seqirus-us.com MCC Code, Month 2017

AFLURIA® QUADRIVALENT (Influenza Vaccine) Important Safety Information

INDICATION
AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in individuals 5 years of age and older.
CONTRAINDICATIONS
  • Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
WARNINGS AND PRECAUTIONS
  • If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT.
ADVERSE REACTIONS
  • In adults 18 through 64 years, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥40%). The most common systemic adverse events were myalgia and headache (≥20%).
  • In adults 65 years of age and older, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥20%). The most common systemic adverse event was myalgia (≥10%).
  • In children 5 through 8 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse event was headache (≥10%).
  • In children 9 through 17 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse events were headache, myalgia, and malaise and fatigue (≥10%).

The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions:

  • In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the PharmaJet Stratis Needle-Free Injection System were tenderness (≥80%), swelling, pain, redness (≥60%), itching (≥20%) and bruising (≥10%). The most common systemic adverse events were myalgia, malaise (≥30%), and headache (≥20%).

Please see accompanying full Prescribing Information for AFLURIA QUADRIVALENT.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


AFLURIA® (Influenza Vaccine) Important Safety Information

INDICATION

AFLURIA is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. AFLURIA is approved for use in persons 5 years of age and older.

CONTRAINDICATIONS
  • Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
WARNINGS AND PRECAUTIONS
  • Administration of CSL’s 2010 Southern Hemisphere influenza vaccine has been associated with increased rates of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years. Febrile events were also observed in children 5 through 8 years of age.
  • If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA should be based on careful consideration of the potential benefits and risks.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Immunocompromised persons may have a diminished immune response to AFLURIA.
ADVERSE REACTIONS
  • In children five through 17 years of age, the most common injection-site adverse reactions when administered by needle and syringe were pain (≥60%), redness (≥20%) and swelling (≥10%). The most common systemic adverse events were headache, myalgia (≥20%), irritability, malaise and fever (≥10%).
  • In adults 18 through 64 years of age, the most common injection-site adverse reactions when administered by needle and syringe were tenderness (≥60%), pain (≥40%), swelling (≥20%), and redness, itching (≥10%). The most common systemic adverse events were muscle aches (≥30%) headache and malaise (≥20%).
  • In adults 18 through 64 years of age, the most common injection-site adverse reactions when administered by the PharmaJet Stratis Needle-Free Injection System up to 7 days post-vaccination were tenderness (≥80%), swelling, pain, redness (≥60%), itching (≥20%) and bruising (≥10%). The most common systemic adverse events within this period were myalgia, malaise (≥30%), and headache (≥20%).
  • In adults 65 years of age and older, when administered by needle and syringe the most common injection-site adverse reactions were tenderness (≥30%) and pain (≥10%). No systemic adverse events occurred in ≥10% of subjects in this age group.

Please see accompanying full Prescribing Information for AFLURIA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

AFLURIA is a registered trademark of Seqirus UK Limited or its affiliates.